231 related articles for article (PubMed ID: 28854279)
21. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
22. PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer.
Takahashi M; Watanabe S; Suzuki R; Arita M; Sato K; Sato M; Sekiya Y; Abe Y; Fujisaki T; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Saida Y; Hokari S; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
Cancer Immunol Immunother; 2022 Jun; 71(6):1357-1369. PubMed ID: 34657194
[TBL] [Abstract][Full Text] [Related]
23. Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo.
Kleindienst P; Brocker T
Immunology; 2005 Aug; 115(4):556-64. PubMed ID: 16011524
[TBL] [Abstract][Full Text] [Related]
24. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
25. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo.
Crossland KD; Lee VK; Chen W; Riddell SR; Greenberg PD; Cheever MA
J Immunol; 1991 Jun; 146(12):4414-20. PubMed ID: 1674958
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.
Rubinstein MP; Su EW; Suriano S; Cloud CA; Andrijauskaite K; Kesarwani P; Schwartz KM; Williams KM; Johnson CB; Li M; Scurti GM; Salem ML; Paulos CM; Garrett-Mayer E; Mehrotra S; Cole DJ
Cancer Immunol Immunother; 2015 May; 64(5):539-49. PubMed ID: 25676709
[TBL] [Abstract][Full Text] [Related]
27. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
28. Different antitumor immunity roles of cytokine activated T lymphocytes from naive murine splenocytes and from dendritic cells-based vaccine primed splenocytes: implications for adoptive immunotherapy.
Zhang S; Wang Q; Li WF; Wang HY; Zhang HJ; Zhu JJ
Eksp Onkol; 2004 Mar; 26(1):55-62. PubMed ID: 15112581
[TBL] [Abstract][Full Text] [Related]
29. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
Wang LX; Shu S; Plautz GE
Cancer Res; 2005 Oct; 65(20):9547-54. PubMed ID: 16230420
[TBL] [Abstract][Full Text] [Related]
30. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
31.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
32. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
33. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.
Baba J; Watanabe S; Saida Y; Tanaka T; Miyabayashi T; Koshio J; Ichikawa K; Nozaki K; Koya T; Deguchi K; Tan C; Miura S; Tanaka H; Tanaka J; Kagamu H; Yoshizawa H; Nakata K; Narita I
Blood; 2012 Sep; 120(12):2417-27. PubMed ID: 22806892
[TBL] [Abstract][Full Text] [Related]
34. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
[TBL] [Abstract][Full Text] [Related]
35. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
36. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
Hu J; Yuan X; Belladonna ML; Ong JM; Wachsmann-Hogiu S; Farkas DL; Black KL; Yu JS
Cancer Res; 2006 Sep; 66(17):8887-96. PubMed ID: 16951206
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Kammula US
Cancer Res; 2015 Aug; 75(16):3216-26. PubMed ID: 26100671
[TBL] [Abstract][Full Text] [Related]
38. CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
Wang LX; Li Y; Yang G; Pang PY; Haley D; Walker EB; Urba WJ; Hu HM
Eur J Immunol; 2010 May; 40(5):1375-85. PubMed ID: 20186876
[TBL] [Abstract][Full Text] [Related]
39. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Bowers JS; Nelson MH; Kundimi S; Bailey SR; Huff LW; Schwartz KM; Cole DJ; Rubinstein MP; Paulos CM
Clin Cancer Res; 2015 Jun; 21(11):2546-57. PubMed ID: 25904754
[TBL] [Abstract][Full Text] [Related]
40. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
